scholarly journals Acquired amegakaryocytic thrombocytopenic purpura induced by percutaneous ethanol injection during treatment of hepatocellular carcinoma: A case report

2015 ◽  
Vol 11 (1) ◽  
pp. 798-800 ◽  
Author(s):  
DING-LUN AI ◽  
BO-TAO LI ◽  
XIAO-MING PENG ◽  
LIN-ZHI ZHANG ◽  
JING-YAN WANG ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Case Report ◽  
Percutaneous Ethanol Injection ◽  
Thrombocytopenic Purpura ◽  
Ethanol Injection

Percutaneous ethanol injection in bleeding hepatocellular carcinoma.

1992 ◽  
Vol 159 (6) ◽  
pp. 1344-1345
Author(s):  
J P Joly ◽  
T Yzet ◽  
J L Dupas ◽  
J P Capron
Keyword(s):  
Hepatocellular Carcinoma ◽  
Percutaneous Ethanol Injection ◽  
Ethanol Injection

scholarly journals Rescue radiofrequency ablation or percutaneous ethanol injection: a strategy for failed RALPPS stage-1 in patients with cirrhosis-related hepatocellular carcinoma

BMC Surgery ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Qiang Wang ◽  
Shu Chen ◽  
Jun Yan ◽  
Torkel Brismar ◽  
Ernesto Sparrelid ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiofrequency Ablation ◽  
Future Liver Remnant ◽  
Percutaneous Ethanol Injection ◽  
Portal Vein Branch ◽  
Liver Size ◽  
Poor Growth ◽  
Liver Remnant ◽  
Ethanol Injection ◽  
Stage 1

Abstract Background The future liver remnant (FLR) faces a risk of poor growth in patients with cirrhosis-related hepatocellular carcinoma (HCC) after stage-1 radiofrequency-assisted ALPPS (RALPPS). The present study presents a strategy to trigger further FLR growth using supplementary radiofrequency ablation (RFA) and percutaneous ethanol injection (PEI). Methods At RALPPS stage-1 the portal vein branch was ligated, followed by intraoperative RFA creating a coagulated avascular area between the FLR and the deportalized lobes. During the interstage period, patients not achieving sufficient liver size (≥ 40%) within 2–3 weeks underwent additional percutaneous RFA/PEI of the deportalized lobes (rescue RFA/PEI) in an attempt to further stimulate FLR growth. Results Seven patients underwent rescue RFA/PEI after RALPPS stage-1. In total five RFAs and eight PEIs were applied in these patients. The kinetic growth rate (KGR) was highest the first week after RALPPS stage-1 (10%, range − 1% to 15%), and then dropped to 1.5% (0–9%) in the second week (p < 0.05). With rescue RFA/PEI applied, KGR increased significantly to 4% (2–5%) compared with that before the rescue procedures (p < 0.05). Five patients proceeded to RALPPS stage-2. Two patients failed: In one patient the FLR remained at a constant level even after four rescue PEIs. The other patient developed metastasis. Except one patient died after RALPPS stage-2, no severe complications (Clavien-Dindo ≥ IIIb) occurred among remaining six patients. Conclusions Rescue RFA/PEI may provide an alternative to trigger further growth of the FLR in patients with cirrhosis-related HCC showing insufficient FLR after RALPPS stage-1. Trial registration Retrospectively registered.

scholarly journals Percutaneous ethanol injection (PEI) in the treatment of small hepatocellular carcinoma (HCC)

1996 ◽  
Vol 14 ◽  
pp. 89-94
Author(s):  
Masaaki Ebara ◽  
Hiroyuki Fukuda ◽  
Masaharu Yoshikawa ◽  
Nobuyuki Sugiura ◽  
Hiromitsu Saisho
Keyword(s):  
Hepatocellular Carcinoma ◽  
Percutaneous Ethanol Injection ◽  
Small Hepatocellular Carcinoma ◽  
Ethanol Injection

Palliative Treatment of Hepatocellular Carcinoma with Transcatheter Arterial Embolization

1993 ◽  
Vol 34 (1) ◽  
pp. 26-29 ◽  
Author(s):  
S. Savastano ◽  
G. P. Feltrin ◽  
D. Neri ◽  
P. da Pian ◽  
M. Chiesura-Corona ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Transcatheter Arterial Embolization ◽  
Palliative Treatment ◽  
Arterial Embolization ◽  
Percutaneous Ethanol Injection ◽  
Ethanol Injection ◽  
History Of ◽  
The Mean ◽  
Hcc Recurrence

Thirty-three consecutive patients with previously untreated hepatocellular carcinoma (HCC) and 6 patients with recurrent HCC were treated with transcatheter arterial embolization (TAE). The patients were not eligible for surgical resection or percutaneous ethanol injection. TAE was performed with Lipiodol Ultra-Fluid, epidoxorubicin and Gelfoam, with a mean of 1.7 treatments per patient. CT was performed 15 days after TAE. The mean cumulative survival was 14.2 months in patients with previously untreated HCC. The survival of patients stages Okuda I and II did not differ significantly (p > 0.05); tumor size did not affect survival (p > 0.05). Two patients with recurrent HCC died 7.0 and 9.3 months after the diagnosis of tumor recurrence; the remaining 4 patients are still alive with a maximum follow-up of 22.5 months from the diagnosis of HCC recurrence. Ten complications occurred in 8 patients, and were controlled by medical therapy. Eleven patients died during the study; no death was related to TAE. The series was not randomized, but comparison with the natural history of HCC suggests that TAE is effective as palliative treatment of advanced or recurrent HCC.

scholarly journals Portal vein thrombosis after percutaneous ethanol injection of hepatocellular carcinoma

2010 ◽  
Vol 102 (11) ◽  
Author(s):  
M. Romero-Gutiérrez ◽  
T. Artaza-Varasa ◽  
R. A. Gómez- Rodríguez ◽  
C. González-de-Frutos ◽  
A. Z. Gómez-Moreno
Keyword(s):  
Hepatocellular Carcinoma ◽  
Portal Vein ◽  
Portal Vein Thrombosis ◽  
Percutaneous Ethanol Injection ◽  
Ethanol Injection ◽  
Vein Thrombosis
Sign in / Sign up

Export Citation Format

Share Document